Qrons Inc (QRON)

Qrons Inc. (OTC: QRON) is a common stock listing on OTC Markets tied to a biotechnology company focused on developing products, treatments, and technologies for neuronal and infectious diseases. The company’s pipeline has included QS100, an injury-specific, 3D-printable implantable mesenchymal stem cell and synthetic hydrogel product candidate intended for penetrating brain injuries, and QS200, an injectable MSCs-synthetic hydrogel being developed for concussions and other diffuse axonal injuries. In January 2025, Qrons Inc. was acquired by First Person Ltd. through a reverse merger transaction. The company was incorporated in 2016 and was previously known as BioLabMart Inc. before adopting the Qrons Inc. name in August 2017. It is based in Long Island City, New York.

Jump directly to the stock analysis sections supported by the latest available data.